Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


18.02.2019

4 BJU Int
2 BMC Cancer
2 Cancer
2 Cancer Lett
1 Cancer Res
1 Curr Treat Options Oncol
1 Eur Radiol
2 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 J Cell Physiol
17 J Urol
1 JAMA
3 Lancet Oncol
1 Magn Reson Imaging
1 Mod Pathol
1 N Engl J Med
1 Nat Rev Urol
4 Oncogene
1 Oncol Rep
2 PLoS One
4 Prog Urol
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. SATHIANATHEN NJ, Philippou YA, Kuntz GM, Konety BR, et al
    Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: A Cochrane Review.
    BJU Int. 2019 Feb 14. doi: 10.1111/bju.14711.
    PubMed     Text format     Abstract available

  2. GLASS AS, Dall'Era MA
    Use of Multi-Parametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14705.
    PubMed     Text format     Abstract available

  3. MERRIEL SWD, Hetherington L, Seggie A, Castle JT, et al
    Best practice in Active Surveillance for men with prostate cancer: A Prostate Cancer UK consensus statement.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14707.
    PubMed     Text format     Abstract available

  4. STABILE A, Orczyk C, Hosking-Jervis F, Giganti F, et al
    Medium term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using HIFU for primary localized prostate cancer.
    BJU Int. 2019 Feb 12. doi: 10.1111/bju.14710.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. TERADA N, Kamoto T, Tsukino H, Mukai S, et al
    The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    BMC Cancer. 2019;19:156.
    PubMed     Text format     Abstract available

  6. CHUNG WS, Lin CL
    Sleep disorders associated with risk of prostate cancer: a population-based cohort study.
    BMC Cancer. 2019;19:146.
    PubMed     Text format     Abstract available


    Cancer

  7. DEKA R, Rose BS, Bryant AK, Sarkar RR, et al
    Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.31982.
    PubMed     Text format     Abstract available

  8. POLACEK LC, Nelson CJ
    Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy: A psychological perspective.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.31980.
    PubMed     Text format    


    Cancer Lett

  9. FENG Y, Sessions EH, Zhang F, Ban F, et al
    Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30084.
    PubMed     Text format     Abstract available

  10. ELLIOTT B, Millena AC, Matyunina L, Zhang M, et al
    Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells.
    Cancer Lett. 2019 Feb 11. pii: S0304-3835(19)30077.
    PubMed     Text format     Abstract available


    Cancer Res

  11. KUMAR R, Bhat TA, Walsh EM, Chaudhary AK, et al
    Cytochrome c-deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.
    Cancer Res. 2019 Feb 14. pii: 0008-5472.CAN-18-2383.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  12. ESTHER J, Maughan BL, Anderson N, Agarwal N, et al
    Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Curr Treat Options Oncol. 2019;20:14.
    PubMed     Text format     Abstract available


    Eur Radiol

  13. BONEKAMP D, Wolf MB, Roethke MC, Pahernik S, et al
    Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.
    Eur Radiol. 2019;29:299-308.
    PubMed     Text format     Abstract available


    Eur Urol

  14. KIM JH, Chung BI
    Re: Timu J. Murtola, Hemo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.
    Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30088.
    PubMed     Text format    

  15. MURTOLA TJ, Syvala H, Riikonen J
    Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvala, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Cl
    Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30090.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  16. SIDDIQUI ZA, Gustafson GS, Ye H, Martinez AA, et al
    5-Year Outcomes of a Single Institution Prospective Trial of 19 Gy Single-Fraction HDR Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 13. pii: S0360-3016(19)30205.
    PubMed     Text format     Abstract available


    J Cell Physiol

  17. FARHOOD B, Mortezaee K, Haghi-Aminjan H, Khanlarkhani N, et al
    A systematic review of radiation-induced testicular toxicities following radiotherapy for prostate cancer.
    J Cell Physiol. 2019 Feb 10. doi: 10.1002/jcp.28283.
    PubMed     Text format     Abstract available


    J Urol

  18. ATALA A
    Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554004.38258.
    PubMed     Text format    

  19. GRIEBLING TL
    Re: Localised Prostate Cancer in Elderly Men Aged 80-89 Years, Findings from a Population-Based Registry.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553998.44096.
    PubMed     Text format    

  20. GRIEBLING TL
    Re: Alzheimer's Disease is Associated with Prostate Cancer: .
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553997.66966.
    PubMed     Text format    

  21. TANEJA SS
    Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000169.
    PubMed     Text format    

  22. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554059.66296.
    PubMed     Text format    

  23. ZELEFSKY MJ, Goldman DA, Reuter V, Kollmeier M, et al
    Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000110.
    PubMed     Text format     Abstract available

  24. ATALA A
    Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554005.76376.
    PubMed     Text format    

  25. DAMODARAN S, Lang JM, Jarrard DF
    Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000117.
    PubMed     Text format     Abstract available

  26. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
    J Urol. 2019;201:528-534.
    PubMed     Text format     Abstract available

  27. WANG CS, Jhan JH, Li CC
    Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Po
    J Urol. 2019;201:627-628.
    PubMed     Text format    

  28. MIRAK SA, Shakeri S, Bajgiran AM, Felker ER, et al
    Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS version 2 Category and Staging with Whole Mount Histopathology Correlation.
    J Urol. 2019;201:496-502.
    PubMed     Text format     Abstract available

  29. LI-SHENG CHEN S, Ching-Yuan Fann J, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
    J Urol. 2019;201:486-495.
    PubMed     Text format     Abstract available

  30. ATALA A
    Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions.
    J Urol. 2019;201:447.
    PubMed     Text format    

  31. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:446-447.
    PubMed     Text format    

  32. TANEJA SS
    Re: A Multicentre Study of 5-Year Outcomes following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    J Urol. 2019;201:443-444.
    PubMed     Text format    

  33. TANEJA SS
    Re: Association between Prostate Magnetic Resonance Imaging and Observation for Low-Risk Prostate Cancer.
    J Urol. 2019;201:443.
    PubMed     Text format    

  34. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
    J Urol. 2019;201:510-519.
    PubMed     Text format     Abstract available


    JAMA

  35. MAHAL BA, Butler S, Franco I, Spratt DE, et al
    Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.
    JAMA. 2019 Feb 11. pii: 2724897. doi: 10.1001/jama.2018.19941.
    PubMed     Text format    


    Lancet Oncol

  36. TOMBAL B, Saad F, Penson D, Hussain M, et al
    Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30898.
    PubMed     Text format     Abstract available

  37. SPRATT DE
    Combination therapies in prostate cancer: proceed with caution.
    Lancet Oncol. 2019 Feb 6. pii: S1470-2045(18)30929.
    PubMed     Text format    

  38. SMITH M, Parker C, Saad F, Miller K, et al
    Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Feb 6. pii: S1470-2045(18)30860.
    PubMed     Text format     Abstract available


    Magn Reson Imaging

  39. GIGANTI F, Stabile A, Giona S, Marenco J, et al
    Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.
    Magn Reson Imaging. 2019 Feb 12. pii: S0730-725X(18)30646.
    PubMed     Text format     Abstract available


    Mod Pathol

  40. VERHOEF EI, van Cappellen WA, Slotman JA, Kremers GJ, et al
    Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns.
    Mod Pathol. 2019 Feb 8. pii: 10.1038/s41379-019-0221.
    PubMed     Text format     Abstract available


    N Engl J Med

  41. FIZAZI K, Shore N, Tammela TL, Ulys A, et al
    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2019 Feb 14. doi: 10.1056/NEJMoa1815671.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  42. SFANOS KS, Joshu CE
    IBD as a risk factor for prostate cancer: what is the link?
    Nat Rev Urol. 2019 Feb 11. pii: 10.1038/s41585-019-0157.
    PubMed     Text format    


    Oncogene

  43. VENKADAKRISHNAN VB, DePriest AD, Kumari S, Senapati D, et al
    Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
    Oncogene. 2019 Feb 11. pii: 10.1038/s41388-019-0732.
    PubMed     Text format     Abstract available

  44. ZHU S, Tian H, Niu X, Wang J, et al
    Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Oncogene. 2019 Feb 15. pii: 10.1038/s41388-019-0750.
    PubMed     Text format     Abstract available

  45. WANG W, Yang X, Dai J, Lu Y, et al
    Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.
    Oncogene. 2019 Feb 12. pii: 10.1038/s41388-019-0736.
    PubMed     Text format     Abstract available

  46. YANG J, Guo Y, Lu C, Zhang R, et al
    Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.
    Oncogene. 2019 Feb 11. pii: 10.1038/s41388-019-0745.
    PubMed     Text format     Abstract available


    Oncol Rep

  47. ZHANG N, Su P, Li X, Xi J, et al
    Downregulated Kruppellike factor 4 expression is associated with the aggressiveness of prostate cancer.
    Oncol Rep. 2019 Jan 22. doi: 10.3892/or.2019.6975.
    PubMed     Text format     Abstract available


    PLoS One

  48. KARLSSON A, Jauhiainen A, Gulati R, Eklund M, et al
    A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.
    PLoS One. 2019;14:e0211918.
    PubMed     Text format     Abstract available

  49. LAI CC, Huang PH, Wang FN, Shen SH, et al
    Histogram analysis of prostate cancer on dynamic contrast-enhanced magnetic resonance imaging: A preliminary study emphasizing on zonal difference.
    PLoS One. 2019;14:e0212092.
    PubMed     Text format     Abstract available


    Prog Urol

  50. ALBISINNI S, Grosman J, Aoun F, Quackels T, et al
    Exploring positive surgical margins after minimally invasive radical prostatectomy: Does body habitus really make a difference ?
    Prog Urol. 2018;28.
    PubMed     Text format     Abstract available

  51. THEVENIAUD PE, Zafar N, Hajj AE, Germain A, et al
    Mid term functional results following surgical treatment of recto-urinary fistulas postprostate cancer treatment.
    Prog Urol. 2018;28:915-920.
    PubMed     Text format     Abstract available

  52. MOUREAUX C, Boucaud-Maitre D, Brureau L, Gourtaud G, et al
    [Pelvimetrics measures as predictives factors of positives surgical margins after robot-assisted laparoscopic prostatectomy].
    Prog Urol. 2018;28:906-914.
    PubMed     Text format     Abstract available

  53. BRUREAU L, Emeville E, Multigner L, Blanchet P, et al
    Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies).
    Prog Urol. 2018;28.
    PubMed     Text format     Abstract available


    Urol Int

  54. PORCARO AB, Tafuri A, Sebben M, Cacciamani G, et al
    Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease.
    Urol Int. 2019 Feb 14:1-9. doi: 10.1159/000496833.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: